Business Context and Reporting Period
InflaRx N.V., a foreign private issuer, filed Form 6-K on March 19, 2026. The filing serves to distribute a press release announcing the Company's full-year 2025 results, key achievements, and expected milestones.
Key Financial Metrics
The provided filing text does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity, but the text of that exhibit is not included in the source material.
Material Changes
No material changes or comparative financial data are disclosed within the body of this Form 6-K. The filing solely acts as a conduit for the attached press release regarding 2025 performance.
Guidance, Outlook, and Risks
Management commentary regarding expected milestones and the outlook for the Company is contained within the attached press release (Exhibit 99.1). This Form 6-K does not explicitly detail risks, contingencies, or unusual items, nor does it provide specific guidance figures.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific 2025 financial results.
- Verify the details of the "expected milestones" mentioned in the announcement.
- Confirm the Company's cash position and burn rate, as these are not stated in the filing summary.
- Check for any updated clinical trial timelines or regulatory expectations referenced in the attached exhibit.